Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan W Friedberg

Showing results (111-120 of 300) with videos related to

Pageof 30
Sort By:
Leukemia & Lymphoma|August 27, 2016
[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practiceIda Wong-Sefidan, Michelle Byrtek, Xiaolei Zhou, et al.
Clinical Immunology (Orlando, Fla.)|June 15, 2014
A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokineticsCarla Casulo, Julie M Vose, William Y Ho, et al.
Ejhaem|November 29, 2023
Overcoming barriers to drug development and enrollment in clinical trials for adolescents and young adults with lymphomaKeri Toner, Carl E Allen, Shweta Jain, et al.
Ejhaem|June 19, 2024
Clonally unrelated primary large B-cell lymphomas separated by over a decade involving the central nervous system and testicle: Possible predisposition to lymphomas of immune-privileged sites?Giby V George, Diana G Aldowitz, Audrey N Jajosky, et al.
Leukemia & Lymphoma|September 18, 2012
The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation studyJulie M Vose, Jonathan W Friedberg, Edmund K Waller, et al.
Leukemia & Lymphoma|November 25, 2020
Safety and efficacy of navitoclax, a BCL-2 and BCL-X<sub>L</sub> inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a studySven de Vos, John P Leonard, Jonathan W Friedberg, et al.
Leukemia & Lymphoma|June 6, 2019
Maximizing the effectiveness of oral therapies in lymphoid cancers: research gaps and unmet needsAlix Y L Zackon, Amy A Ayers, Katherine A Yeager, et al.
Blood Advances|January 23, 2023
Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemiaDanielle S Wallace, Clive S Zent, Andrea M Baran, et al.
Leukemia & Lymphoma|October 26, 2011
High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab eraMakiko Ban-Hoefen, Jennifer L Kelly, Steven H Bernstein, et al.
Molecular Cancer Therapeutics|March 14, 2012
Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivoGirija Dasmahapatra, Dmitry Lembersky, Minkyeong P Son, et al.
Pageof 30

Showing results (111-120 of 300) with videos related to

Sort By:
Pageof 30
Leukemia & Lymphoma|August 27, 2016
[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practiceIda Wong-Sefidan, Michelle Byrtek, Xiaolei Zhou, et al.
Clinical Immunology (Orlando, Fla.)|June 15, 2014
A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokineticsCarla Casulo, Julie M Vose, William Y Ho, et al.
Ejhaem|November 29, 2023
Overcoming barriers to drug development and enrollment in clinical trials for adolescents and young adults with lymphomaKeri Toner, Carl E Allen, Shweta Jain, et al.
Ejhaem|June 19, 2024
Clonally unrelated primary large B-cell lymphomas separated by over a decade involving the central nervous system and testicle: Possible predisposition to lymphomas of immune-privileged sites?Giby V George, Diana G Aldowitz, Audrey N Jajosky, et al.
Leukemia & Lymphoma|September 18, 2012
The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation studyJulie M Vose, Jonathan W Friedberg, Edmund K Waller, et al.
Leukemia & Lymphoma|November 25, 2020
Safety and efficacy of navitoclax, a BCL-2 and BCL-X<sub>L</sub> inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a studySven de Vos, John P Leonard, Jonathan W Friedberg, et al.
Leukemia & Lymphoma|June 6, 2019
Maximizing the effectiveness of oral therapies in lymphoid cancers: research gaps and unmet needsAlix Y L Zackon, Amy A Ayers, Katherine A Yeager, et al.
Blood Advances|January 23, 2023
Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemiaDanielle S Wallace, Clive S Zent, Andrea M Baran, et al.
Leukemia & Lymphoma|October 26, 2011
High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab eraMakiko Ban-Hoefen, Jennifer L Kelly, Steven H Bernstein, et al.
Molecular Cancer Therapeutics|March 14, 2012
Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivoGirija Dasmahapatra, Dmitry Lembersky, Minkyeong P Son, et al.
Pageof 30